Orally available sphingosine 1-phosphate receptor agonists...

Details Orally available sphingosine 1-phosphate receptor agonists... Orally available sphingosine 1-phosphate receptor agonists...

2004-11-03

2009-12-29

Saeed, Kamal A (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S205000, C548S235000, C548S335100, C514S365000, C514S374000, C514S396000

Reexamination Certificate

active

07638637

ABSTRACT:
The present invention relates to S1P analogs that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure (I) wherein R11is C5-C18alkyl or C5-C18alkenyl; Q is selected from the group consisting of C3-C6optionally substituted cycloalkyl, C3-C6optionally substituted heterocyclic, C3-C6optionally substituted aryl C3-C6optionally substituted heteroaryl and; R2is selected from the group consisting of H, C1-C4alkyl, (C1-C4alkyl)OH and (C1-C4alkyl)NH2; R23is H or C1-C4alkyl, and R15is a phosphonate ester or a phosphate ester or a pharmaceutically acceptable salt or tautomer thereof.

REFERENCES:
patent: 3153092 (1964-10-01), Burger
patent: 4939130 (1990-07-01), Jaeggi et al.
patent: 5405988 (1995-04-01), Klar et al.
patent: 5773475 (1998-06-01), Kohn
patent: 6069251 (2000-05-01), Thurkauf et al.
patent: 6875757 (2005-04-01), Miller et al.
patent: 7060697 (2006-06-01), Marsilje et al.
patent: 7064217 (2006-06-01), Macdonald et al.
patent: 7241790 (2007-07-01), Lynch et al.
patent: 2004/0224941 (2004-11-01), Seko et al.
patent: 2005/0032744 (2005-02-01), Michaelis et al.
patent: 2005/0043386 (2005-02-01), Nishi et al.
patent: 2005/0107447 (2005-05-01), Lynch et al.
patent: 2006/0046979 (2006-03-01), Foster et al.
patent: 2006/0122181 (2006-06-01), Ikemoto et al.
patent: 2006/0135786 (2006-06-01), Saha et al.
patent: 2006/0211656 (2006-09-01), Albert et al.
patent: 2006/0223866 (2006-10-01), Evindar et al.
patent: 2007/0088002 (2007-04-01), Lynch et al.
patent: 2007/0191313 (2007-08-01), Beard et al.
patent: 1 553 091 (2005-07-01), None
patent: 1602660 (2005-12-01), None
patent: 950388 (1964-02-01), None
patent: 06135935 (1994-05-01), None
patent: 06135936 (1994-05-01), None
patent: 2002-316985 (2002-10-01), None
patent: 2004 307442 (2004-04-01), None
patent: WO 99/35259 (1999-07-01), None
patent: WO 01/60819 (2001-08-01), None
patent: WO 02/064616 (2002-08-01), None
patent: WO 02/076995 (2002-10-01), None
patent: WO 02/092068 (2002-11-01), None
patent: WO 03/059880 (2003-07-01), None
patent: WO 03/061567 (2003-07-01), None
patent: WO 2004/010987 (2003-07-01), None
patent: WO 2004/017917 (2004-03-01), None
patent: WO 2004/024673 (2004-03-01), None
patent: WO 2004/028521 (2004-04-01), None
patent: WO 2004/047743 (2004-06-01), None
patent: WO 2004/096752 (2004-11-01), None
patent: WO 2004/096757 (2004-11-01), None
patent: WO 2004/103279 (2004-12-01), None
patent: WO 2004/103306 (2004-12-01), None
patent: WO 2005/032465 (2005-04-01), None
patent: WO 2005/118523 (2005-12-01), None
patent: WO 2006/001463 (2006-01-01), None
patent: WO 2006/020951 (2006-02-01), None
patent: WO 2006/063033 (2006-06-01), None
patent: WO 2006/088944 (2006-08-01), None
patent: WO 2007/085451 (2007-08-01), None
patent: WO 2007/086001 (2007-08-01), None
patent: WO 2007/091396 (2007-08-01), None
patent: WO 2007/092638 (2007-08-01), None
patent: WO 2008/064315 (2008-05-01), None
patent: WO 2008/064320 (2008-05-01), None
patent: WO 2008/064337 (2008-05-01), None
patent: WO 2009/023854 (2009-02-01), None
patent: WO 2009/043013 (2009-04-01), None
International Search Report for PCT/US2004/036563.
Bandini, Marco et al., “An Effective and Useful Synthesis of Enantiomerically Enriched Arylglycinols”,Eur. J. Chem. 2001, 1937-1942.
Beilstein, XP-002380276.
Bertus, Phillipe et al., “New and easy route to primary cyclopropylamines from nitriles”,Chem Commun, 2001, 1792-1793.
Brinkmann, V. et al., V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., Foster, C. A., Zollinger, M., and Lynch, K. R. (2002)J Biol Chem277, 21453-21457.
Brinkmann, V., Pinschewer, D. D., Feng, L., and Chen, S. (2001)Transplantation72, 764-769.
Burger, Alfred et al., “1-Methyl-2-phenylcyclopropylamine”,Journal of Medicine and Pharmaceutical Chemistry, vol. 4, No. 3, 1961.
Chiba, K., Yanagawa, Y., Masubuchi, Y., Kataoka, H., Kawaguchi, T., Ohtsuki, M., and Hoshino, Y. (1998)J Immunol160, 5037-5044.
Clair, T., Aoki, J., Koh, E., Bandle, R. W., Nam, S. W., Ptaszynska, M. M., Mills, G. B., Schiffmann, E., Liotta, L. A., and Stracke, M. L. (2003).
Choi, D. et al., “Synthesis and Anticonvulsant Activities ofN-Benzyl-2-acetamidopropionamide”,J Med Chem39, 1996, 1907-1916.
Foss, F. et al., “Synthesis, stability, and implications of phosphothioate agonists of sphingosine-1-phosphate receptors”,Bioorganic&Medicinal Chemistry15, 2005, 4470-4474.
Im, D. S. et al., “Characterization of the Human and Mouse Sphingsine 1-Phosphate Receptor, S1P5(Edg-8): Structure—Activity Replationship of Sphingosine 1-Phosphate Receptors”, Biochemistry 40, 2001, 14053-14060.
Maki, T. et al., “Prevention of Autoimmune Diabetes By FTY720 in Nonobese Diabetic Mice”, (2002)Transplantation74, 1684-1686.
Maki, T. et al., “Prevention and Cure of Autoimmune Diabetes in Nonobese Diabetic Mice by Continuous Administration of FTY720”, (2005)Transplantation77, 1051-1055.
Clemens, J. et al., Bioorg. Med. Chem. Lett. 2004, vol. 14, pp. 4903-4906.
Kotera et al., Chem. Abst.: Registry Record 19352-04-6, (2008).
Brinkmann, V., Pinschewer, D. D., Feng, L., and Chen, S. (2001)Transplantation72, 764-769.
Maki, T., Gottschalk, R., and Monaco, A.P. (2002)Transplantation74, 1684-1686.
International Search Report for PCT/US2004/036563, (2006).
Clair, T., Aoki, J., Koh, E., Bandle, R. W., Nam, S. W., Ptaszynska, M. M., Mills, G. B., Schiffmann, E., Liotta, L. A., and Stracke, M. L. (2003)Cancer Res63, 5446-5453.
Clemens, J. J., Davis, M. D., Lynch, K. R., and Macdonald, T. L. (2003)Bioorg Med Chem Lett13, 3401-3404.
Clemens, Jeremy et al., “Synthesis of 4(5)-phenylimidazole-based analogs of sphingosine-1-phosphate and FTY720: Discovery of potent S1P1receptor agonists”,Bioorganic&Medicinal Chemistry Letters15 (2005) 3568-3572.
Crosignani, Stefano et al., “4-Naphthyl-Substituted Bis(Oxazoline): a New Easily Recoverable and Efficient Chiral Ligand in Asymetric Catalysis of the Diels-Alder Reaction”,Tetrahedron54 (1998) 15721-15730.
Davis, Michael D. et al., “Sphingosine 1-Phosphate Analogs as Receptor Antagonists”,The Journal of Biological Chemistry, vol. 280, No. 11, 2005,9833-9841.
Forrest, M., Sun, S. Y., Hajdu, R., Bergstrom, J., Card, D., Doherty, G., Hale, J., Keohane, C., Meyers, C., Milligan, J., Mills, S., Nomura, N., Rosen, H., Rosenbach, M., Shei, G. J., Singer, II, Tian, M., West, S., White, V., Xie, J., Proia, R. L., and Mandala, S. (2004)J Pharmacol Exp Ther309, 758-768.
Foss, Frank W. et al., “Synthesis and biological evaluation of γ-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists”,Bioorganic&Medicinal Chemistry15, 2007, 663-677.
Fujino, M., Funeshima, N., Kitazawa, Y., Kimura, H., Amemiya, H., Suzuki, S., and Li, X. K. (2003)J Pharmacol Exp Ther305, 70-77.
Graler, M. H., and Goetzl, E. J. (2004)FASEB18, 551-553.
Hale, Jeffrey J. et al., “Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720”,Bioorganic&Medicinal Chemistry Letters14, 2004, 3351-3355.
Hale, J. J., Doherty, G., Toth, L., Mills, S. G., Hajdu, R., Ann Keohane, C., Rosenbach, M., Milligan, J., Shei, G. J., Chrebet, G., Bergstrom, J., Card, D., Forrest, M., Sun, S. Y., West, S., Xie, H., Nomura, N., Rosen, H., and Mandala, S. (2004)Bioorg Med Chem Lett14, 3501-3505.
Hale, J. J., Doherty, G., Toth, L., Li, Z., Mills, S. G., Hajdu, R., Ann Keohane, C., Rosenbach, M., Milligan, J., Shei, G. J., Chrebet, G., Bergstrom, J., Card, D., Rosen, H., and Mandala, S. (2004)Bioorg Med Chem Lett14, 3495-3499.
Hale, Jeffrey J. et al., “A Rational Utilization of High-Throughput Screening Affords Selective, Orally Bioavailable 1-Benzy1-3-carboxyazetidine Sphingosine-1-phophate-1 Receptor Agonists”,J Med Chem, 2004, 47, 6662-6665.

Affiliated with

Also associated with

Rating

Orally available sphingosine 1-phosphate receptor agonists... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Orally available sphingosine 1-phosphate receptor agonists..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Orally available sphingosine 1-phosphate receptor agonists... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4130851